Mobocertinib Dose Rationale in Patients With Metastatic NSCLC With EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2622
Abstract: Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20ins) mutations previously… read more here.
Keywords: molar sum; response; egfr exon; exposure ... See more keywords
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00722-0
Abstract: Epidermal growth factor receptor (EGFR) exon 19 deletions (19dels) appear in a large number of variants, which has not been distinguished in previously published trials despite differences in deletion and insertion locations. The aim of… read more here.
Keywords: exon 19dels; egfr exon; different egfr; first generation ... See more keywords
Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.06.019
Abstract: Introduction: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR‐activating alterations relatively insensitive to first‐ and second‐generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests these patients may benefit from… read more here.
Keywords: generation egfr; egfr; comprehensive genomic; egfr exon ... See more keywords
EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.10.007
Abstract: OBJECTIVES Contrasting other EGFR mutations (EGFRm) in lung adenocarcinomas, insertions in exon 20 (exon20ins) are generally associated with resistance to targeted therapy, limiting therapeutic options and impoverishing the prognosis compared to other EGFRm. We sought… read more here.
Keywords: geno1 clicap; common egfrm; egfr exon; lung adenocarcinomas ... See more keywords
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.11.039
Abstract: OBJECTIVES Epidermal growth factor receptor (EGFR) mutation-positive lung cancer accounts for a significant subgroup of non-small cell lung cancers (NSCLC). Approximately 4-10% of EGFR mutations in NSCLC are EGFR exon 20 insertion mutations, which are… read more here.
Keywords: combination; egfr; insertion mutations; exon insertion ... See more keywords
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-98275-3
Abstract: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients with Exon20ins… read more here.
Keywords: egfr exon; lung cancer; cell lung; non small ... See more keywords
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2083326
Abstract: Abstract Introduction EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC) is rare, has a poor prognosis, and outcomes are not fully established. We describe and evaluate outcomes from real-world and clinical evidence in… read more here.
Keywords: exon insertion; insertion; insertion mutation; egfr exon ... See more keywords
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2016397
Abstract: ABSTRACT Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations following progression on chemotherapy,… read more here.
Keywords: exon insertion; egfr exon; small cell; non small ... See more keywords
Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001274
Abstract: EGFR exon 20 insertion mutation is a rare mutation subtype of EGFR mutations, with no approved treatment in China so far. The clinical treatments of advanced EGFR exon 20 insertion mutations in non-small cell lung… read more here.
Keywords: exon insertion; treatment; insertion mutations; egfr exon ... See more keywords
Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13431
Abstract: The role of the epidermal growth factor receptor (EGFR) mutation status testing in lung squamous cell carcinoma (SqCC) remains controversial. Evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. Here,… read more here.
Keywords: egfr exon; cell carcinoma; squamous cell; t790m ... See more keywords
Frequent EGFR exon 20 insertion in the so-called peripheral-type squamous cell neoplasm of uncertain malignant potential: a variant of bronchiolar adenoma or under-recognised entity?
Sign Up to like & getrecommendations! Published in 2023 at "Histopathology"
DOI: 10.1111/his.14890
Abstract: INTRODUCTION Herein we describe a series of rare peripheral pulmonary neoplasms temporarily termed "peripheral type squamous cell neoplasm of uncertain malignant potential (PSCN-UMP)" and investigate their relationship to bronchiolar adenoma (BA) and squamous cell carcinoma… read more here.
Keywords: frequent egfr; squamous cell; pscn umps; egfr exon ... See more keywords